AFTER a perfect record in this year’s championship, Ballygalget will be hoping that they can cap their season off in style ...
Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that has completed Phase III pivotal trials for the treatment of lung infections resulting from S. aureus ...
Aridis Pharmaceuticals Inc (NASDAQ: ARDS) shares are gaining after announcing positive European Medicines Agency feedback on its proposed single confirmatory Phase 3 study of investigational ...
This is the first randomized controlled trial investigating the efficacy and safety of low-dose prolonged methylprednisolone administration in early ARDS. This study tested a pathophysiologic ...
The second phase of the proposals will involve provision ... It confirmed that the Ards Minor Injury Unit will close at 17:00 BST on 1 September, with the new unit to open on 6 September 08: ...
This Phase 2 clinical study will evaluate paridiprubart (EB05) in hospitalized patients with acute respiratory distress syndrome (ARDS) due to a variety of causes. This BARDA-funded project is ...
Meta-analysis of subjects from 4 randomized clinical trials supports the potential of enobosarm to optimize weight loss Start ...
A Charlottesville startup is developing new drugs that target inflammation for people with acute lung injuries. It's received ...
To schedule a meeting with Edesa during the conferences, please contact conference organizers or the company directly at [email protected].
The collaboration outlines plans for multiple in vivo studies, designed to test opaganib as a potential medical countermeasure to treat phosgene i ...
It develops products for the treatment of obstructive sleep apnoea (OSA), traumatic brain injury (TBI) and concussion, lung inflammation (ARDS ... which has completed Phase IIb clinical trial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback